What is dNovo?
Founded in 2018 and headquartered in Silicon Valley, California, dNovo is dedicated to pioneering cell technology solutions for the treatment of baldness. Operating in the pre-clinical stage, the company's core mission revolves around developing innovative therapies to address hair loss. This focus places dNovo at the intersection of biotechnology and regenerative medicine, a rapidly evolving sector with substantial market potential.
How much funding has dNovo raised?
dNovo has raised a total of $2.7M across 1 funding round:
Angel/Seed
$2.7M
Angel/Seed (2022): $2.7M with participation from Soma Capital Partners, Yintai Investment Company, Felicis Ventures, and Y Combinator
Key Investors in dNovo
Soma Capital Partners
Soma Capital Partners is a San Francisco-based investment firm that specializes in owning and operating commercial real estate focused on innovation and community building. The firm invests across the risk spectrum, supporting transformative spaces and vibrant communities.
Felicis Ventures
Feliciss is a Menlo Parkbased venture capital firm that raises multistage funds to invest in early and growthstage technology companies across sectors such as SaaS, AI, fintech, and consumer, typically leading seed and Series A rounds and supporting founders through scaleup and exit.
Y Combinator
Established in 2005 and located in Mountain View, California, Y Combinator provides seed funding for startup businesses and to gauge investors for businesses.
What's next for dNovo?
The recent major strategic investment indicates dNovo's progression towards scaling its operations and advancing its research and development pipeline. This capital infusion is likely to accelerate the company's efforts in clinical trials and further solidify its position in the competitive biotech landscape. The backing from established investors suggests confidence in dNovo's scientific approach and its potential to disrupt the hair loss treatment market.
See full dNovo company page
